NOVOB80 Stock Price and Chart — SET:NOVOB80

Overview

Financials News Ideas Discussions Technicals Seasonals Bonds

Key facts today

Novo Nordisk's stock was downgraded by Barclays, lowering the target price from 700 to 375 kroner. Shares dropped 3.4% to 335.10 kroner due to issues with its obesity drug.

Novo Nordisk warned of lower profits due to increased competition and pricing pressures in the insulin market, along with changes in U.S. reimbursement policies, analysts report.

Jefferies analysts warned that Novo Nordisk's profit alert could impact views on the obesity market, citing weak growth for its Wegovy and Ozempic drugs in the U.S.

Analyze the impact Analyze the impact

About NOVO NORDISK B A/S

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Check out other big names from the same industry as NOVOB80.